as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹382.15
Change
-4.85 (-1.25%)
Open
₹387.5
Prev. Close
₹387.0
Day High
₹388.7
Day Low
₹380.5
Volume Analysis
Traded
2,694,397
Delivered
1,390,773
Delivery %
51.62%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (2)
- •Low return on equity (1.4%)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹395.26 | ₹391.98 | ₹387.06 | ₹383.78 | ₹378.86 | ₹375.58 | ₹370.66 |
| Fibonacci | ₹391.98 | ₹388.85 | ₹386.91 | ₹383.78 | ₹380.65 | ₹378.71 | ₹375.58 |
| Camarilla | ₹384.41 | ₹383.65 | ₹382.9 | ₹383.78 | ₹381.4 | ₹380.65 | ₹379.9 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-1.44%
1 Week
-3.25%
1 Month
-7.04%
3 Months
-8.64%
6 Months
+4.64%
1 Year
+12.76%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹106.04
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
1.21%
Net margin 2.4% × asset turnover 0.27x × equity multiplier 1.86x
Company Overview
Sector
Healthcare
Market Cap
₹64,275 Cr
P/E (TTM)
88.4
ROE
1.4%
Book Value
₹210.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Biocon Limited. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 57/100. The strongest factor is Financial Strength (91/100), while Valuation (25/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%); low return on equity (1.4%); promoter holding is falling.
TopFund Score — Fundamentals Quality
57/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Company has low interest coverage ratio.
- −Company has a low return on equity of 3.49% over last 3 years.
- −Company might be capitalizing the interest cost
- −Dividend payout has been low at 10.9% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
On Sept. 21, 2026, Biocon’s Pebrilzo® pertuzumab biosimilar received EMA CHMP positive opinion; EU approval pending.
Biocon remitted final dividend of ₹0.50 per share for FY2025-26, approved at 48th AGM on August 6, 2026.
Biocon schedules investor roadshow in Mumbai on 11-Sep-26.
Biocon wins 10-year Pertuzumab supply contract in Brazil, with milestone payments and revenue share.
Biocon to meet investors at Nomura Asian Credit Corporate Day 2026 on 04-Sep-26.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Expenses + | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 |
| Operating Profit | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 |
| OPM % | 20.0% | 21.0% | 23.0% | 23.0% | 18.0% | 19.0% | 20.0% | 24.0% | 19.0% | 19.0% | 20.0% | 23.0% | 20.0% |
| Other Income + | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 |
| Interest | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 |
| Depreciation | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 |
| Profit before tax | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 |
| Tax % | 19.0% | 19.0% | 7.0% | 30.0% | 25.0% | 72.0% | 48.0% | 6.0% | 8.0% | 22.0% | -24.0% | 20.0% | -7.0% |
| Net Profit + | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 |
| EPS in Rs | 1 | 1 | 6 | 1 | 5 | 0 | 0 | 3 | 0 | 1 | 1 | 1 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 | 17,321 |
| Expenses + | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,696 | 5,562 | 6,391 | 8,762 | 11,540 | 12,008 | 13,456 | 13,785 |
| Operating Profit | 696 | 390 | 980 | 829 | 1,394 | 1,604 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,471 | 3,536 |
| OPM % | 23.0% | 12.0% | 25.0% | 20.0% | 25.0% | 25.0% | 22.0% | 22.0% | 22.0% | 22.0% | 21.0% | 21.0% | 20.0% |
| Other Income + | 158 | 639 | 173 | 228 | 340 | 199 | 260 | 72 | 18 | 853 | 1,217 | -76 | -82 |
| Interest | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 990 | 927 |
| Depreciation | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,957 | 2,049 |
| Profit before tax | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 448 | 479 |
| Tax % | 15.0% | 19.0% | 19.0% | 26.0% | 17.0% | 27.0% | 21.0% | 22.0% | 28.0% | 15.0% | 24.0% | 18.0% | — |
| Net Profit + | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 | 416 |
| EPS in Rs | 4 | 5 | 5 | 3 | 8 | 6 | 6 | 5 | 4 | 9 | 8 | 2 | 3 |
| Dividend Payout % | 20.0% | 18.0% | 10.0% | 16.0% | 7.0% | 0.0% | 0.0% | 9.0% | 39.0% | 6.0% | 6.0% | 21.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 33,221 |
| Borrowings + | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 18,362 | 15,434 |
| Other Liabilities + | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 18,534 | 13,943 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 63,409 |
| Fixed Assets + | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 36,486 |
| CWIP | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 | 6,987 |
| Investments | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 1,779 |
| Other Assets + | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,941 | 18,157 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 63,409 |
| Equity Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 810 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,852 | 2,954 | 4,061 | 1,994 |
| Cash from Investing Activity + | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 | -1,883 |
| Cash from Financing Activity + | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 | -924 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 | -812 |
| CFO/OP | 49 | 158 | 86 | 104 | 104 | 101 | 86 | 80 | 86 | 101 | 139 | 64 |
| Free Cash Flow | -627 | -246 | 32 | -251 | -337 | -546 | -577 | -746 | 129 | 1,046 | 1,718 | 82 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.39% | 0.33% | 0.32% | 0.28% | 0.25% | 0.22% | 0.21% | 0.18% | 0.14% | 0.12% | 0.09% | 0.05% |
| Public | 16.92% | 17.96% | 19.74% | 18.9% | 18.74% | 18.11% | 17.77% | 16.51% | 16.7% | 16.34% | 23.4% | 23.75% |
| Promoters | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% | 54.45% | 44.91% | 44.68% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.03% | 0.03% | 0.05% | 0.05% |
| FII | 7.97% | 6.55% | 5.63% | 5.9% | 5.93% | 5.66% | 5.67% | 6.04% | 6.61% | 7.39% | 7.52% | 8.14% |
| DII | 14.08% | 14.51% | 13.69% | 14.29% | 14.44% | 15.36% | 15.73% | 22.83% | 22.06% | 21.67% | 24.01% | 23.33% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Biocon Limited. (this stock) | 64,275 | 88.4 | 1.88 | 1.4% |
| Alkem Laboratories Ltd. | 63,680 | 28.0 | 4.61 | 18.9% |
| Aster Dm Quality Care Ltd | 66,312 | 184.0 | 9.38 | 11.3% |
| Fortis Healthcare Ltd | 66,565 | 62.4 | 6.71 | 11.2% |
| Glenmark Pharmaceuticals | 69,000 | 22.1 | 6.56 | 23.6% |
| Ipca Laboratories Ltd | 50,650 | 36.9 | 6.28 | 15.7% |
| Anthem Biosciences Ltd | 49,633 | 83.6 | 16.25 | 22.3% |
Which Mutual Funds Hold Biocon Limited.?
Frequently Asked Questions about Biocon Limited.
Biocon Limited. (BIOCON) closed at ₹382.15 on NSE on 25 September 2026, down 4.85 (1.25%) from the previous close.
Biocon Limited. trades on the NSE (National Stock Exchange of India) under the symbol BIOCON.
Biocon Limited. has a trailing twelve-month P/E (price-to-earnings) ratio of 88.4.
Biocon Limited. has a dividend yield of 0.13%.
Biocon Limited.'s 52-week high is ₹447.0 and its 52-week low is ₹337.0.
Biocon Limited. has a market capitalisation of ₹64,275 crore.
Biocon Limited. has a TopFund Quality Score of 57/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Biocon Limited.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.